Administration of Fibrinogen Concentrate for Refractory Bleeding
Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
Platelet transfusions are widely employed to prevent or treat bleeding episodes in patients
with thrombocytopenia. Patients with bone marrow failure secondary to haematological
malignancy and chemotherapy frequently receive prophylactic platelet transfusion when
platelet level reaches 10x109.L-1, to avoid spontaneous major bleeding. Due to immune or
nonimmune factors, platelet refractoriness may be observed and is defined as a repeated
suboptimal response to platelet transfusions with lower-than-expected post-transfusion count
increments. The management of patients with alloimmunization is complex and prophylactic
platelet support is no longer indicated. Therefore, platelet refractoriness remains a
clinically challenging complication.